Introduction
Alzheimer's disease (AD) is the leading cause of dementia and is characterized by the progressive decline, and ultimately, loss, of multiple cognitive functions (Fratiglioni et al., 1999; Small et al., 1997) . Characteristic neurofibrillary tangles and deposits of Aβ have been observed in the neocortical brain structures of AD patients (Hardy and Higgins, 1992) , and Aβ is believed to be a pivotal mediator of neuronal degeneration, leading to impaired cognitive function (Hardy, 2006; Mattson, 2004) . In addition, glutamate toxicity is involved in the pathogenesis of various neurodegenerative disorders, including AD (Rothman and Olney, 1995) . For example, glutamate transporter activity is decreased in the postmortem brain of patients with AD (Masliah et al., 1996) , and cerebrospinal fluid glutamate levels are higher in patients with AD (Pomara et al., 1992) .
The administration of bFGF into the hippocampus has been shown to inhibit neuronal damage and spatial learning deficits in a rat model of AD (Noshita et al., 2012) . In this study, Aβ peptide was injected into the hippocampus, followed by an injection of ibotenate -an agonist of the N-methyl-D-aspartate (NMDA) receptor -into the same site. The results of this study therefore suggested that bFGF contributes to the treatment of AD. However, bFGF is a bioactive peptide with a short half-life in the blood and poor blood-brain barrier permeability. Furthermore, the administration of bFGF may lead to leukocytosis and decreased blood pressure in humans (Bogousslavsky et al., 2002) . It is therefore critical to consider these physiological properties when constructing strategies for the practical administration of bFGF.
SUN11602 is a novel aniline derivative that exhibits bFGF-like neuroprotective effects (Murayama et al., 2013) . The specific FGF receptor-1 (FGFR1) tyrosine kinase inhibitor PD166866 abolishes the receptor-mediated neuroprotective effects elicited by SUN11602. SUN11602 enhances the phosphorylation of FGFR1 and extracellular signal-regulated kinase 1/2 (ERK1/2) in cerebrocortical neurons. The pharmacokinetic properties of SUN11602 in male Sprague Dawley (SD) rats and in male beagle dogs are excellent, in that bioavailability of orally administered SUN11602 is 465% in all animals investigated. Thus, it seems reasonable to consider SUN11602 as a candidate compound for protecting vulnerable neurons in various diseases of the central nervous system.
We report here the finding that SUN11602, like bFGF, induces neurite outgrowth of neurons. First, oral administration of SUN11602 improved cognitive performance in the Y-maze and water maze tasks. Second, it decreased the number of PTBBS, a gliosis maker, in the hippocampus of an AD rat model induced by Aβ 1-40 and ibotenate. These findings indicate the therapeutic relevance of SUN11602 for progressive neurodegenerative diseases such as AD.
Results

Neurite outgrowth by SUN11602
The effect of SUN11602 on neurite outgrowth was examined using primary cultures of rat hippocampal neurons (Fig. 1) .
Because neurite outgrowth could simply be secondary to improved neuronal survival, we examined neurite length per cell body, using the IN Cell Analyzer 1000 in the neurite outgrowth detection program. As shown in Fig. 1a , both bFGF and SUN11602 apparently induced neurite outgrowth. The quantification of results revealed that SUN11602 significantly increased neurite outgrowth at a concentration of 1 μM, and the extent was equivalent to the effect of bFGF at 1 ng/ml (Fig. 1b) .
2.2.
The effect of SUN11602 on cognitive deficits in hippocampal-lesioned rats: the Y-maze test
In our previous studies, we established a rat AD model with hippocampal tissue damage, by using sequential treatments with aggregated Aβ 1-40 and ibotenate (Nakamura et al., 2006; Noshita et al., 2012) . We have shown that this model is useful for evaluating pharmacological effects across histological, behavioral, and biochemical analyses under a variety of experimental conditions. In the present study, we investigated the effect of SUN11602 on short term and spatial working memory using this AD model. Fig. 2 shows the results of the Y-maze test performed 32 days after administration of Aβ 1-40 . The treatment of rats with Aβ 1-40 and ibotenate significantly decreased the ratio of spontaneous alterations (Fig. 2b) , without affecting the total number of arm entries (Fig. 2a) , implying impaired working memory. A single oral administration of SUN11602 24 h after the Aβ 1-40 treatment reversed the decrease in the spontaneous alteration ratio in a dose-dependent manner, and this was statistically significant at 1 mg/kg. The administration of SUN11602 did not affect the number of total arm entries (Fig. 2a) .
2.3.
The effect of SUN11602 on cognitive deficits in hippocampal-lesioned rats: the water-maze task
The water maze task was used to investigate learning and longterm spatial reference memory, using the rat AD model induced by Aβ 1-40 and ibotenate. The task was performed over four days, and commenced 35 days after the Aβ 1-40 treatment. As shown in Fig. 3a , the mean escape latency (MEL) recorded during the acquisition training phase was significantly prolonged by sequential injections of Aβ 1-40 and ibotenate into the hippocampus, demonstrating impaired learning. The administration of SUN11602 inhibited the increased MEL induced by Aβ 1-40 and ibotenate (Fig. 3a) . The effects of SUN11602 were statistically significant between days 2-4 and days 3-4 of the training period, at 10 mg/kg and 1 mg/kg, respectively. In a single probe trial performed 2 h after the final acquisition trial, the number of annulus crossings was significantly decreased following sequential injections of Aβ 1-40 and ibotenate, indicating a memory impairment. SUN11602 treatment showed a trend toward inhibiting this decline in the number of annulus crossings (Fig. 3b) . SUN11602 did not affect the swimming speed of rats (data not shown).
2.4.
Protective effects of SUN11602 on hippocampal tissue damage Peripheral-type benzodiazepine-binding sites (PTBBS) have been established as a quantitative marker for severity of b r a i n r e s e a r c h 1 5 8 5 ( 2 0 1 4 ) 1 5 9 -1 6 6 neural tissue damage in the brain (Baudry and Altar, 1991; Venneti et al., 2006) . We estimated the number of PTBBS in vitro to quantify the extent of hippocampal tissue damage following completion of the water maze task. The number of PTBBS in the hippocampal tissue was significantly increased in the hippocampal-lesioned rats compared with a sham group (Fig. 4a) . SUN11602 prevented the increase in the number of PTBBS in a dose-dependent manner, and this effect was statistically significant at Z1 mg/kg (Fig. 4a ). There was a high correlation between the number of PTBBS and escape latency in the water maze task of sham rats and hippocampal-lesioned rats (r¼0.73) (Fig. 4b) .
Discussion
The present study demonstrated the neuroprotective effects of the novel aniline compound SUN11602 on rat hippocampal neurons in vivo. SUN11602 also induced neurite outgrowth of the primarily cultured hippocampal neurons, consistent with the knowledge that bFGF accelerates neurite outgrowth and branching of cultured hippocampal neurons (Ikegaya et al., 2000; Katsuki et al., 2000) . It has been reported that transgenic mice overexpressing human amyloid precursor protein do not show any significant neuronal cell loss, despite large accumulations of fibrillar Aβ (Games et al., 1995; Hsiao et al., 1996) . These observations suggest that Aβ alone is not sufficient to cause drastic neuronal loss, thus additional factors are necessary for in vivo neurodegeneration. Glutamate transporter activity is known to be decreased in the postmortem brain of patients with AD (Masliah et al., 1996) , and the level of glutamate in the cerebrospinal fluid in patients with AD is higher (Pomara et al., 1992) . We have previously shown that sequential injections of aggregated Aβ 1-40 and ibotenate (an NMDA receptor agonist) into the hippocampus induces significant neuronal cell death and a learning deficit in rats, while an injection of Aβ or ibotenate alone at the same concentration does not (Nakamura et al., 2006; Noshita et al., 2012) . Others have also reported similar synergistic effects of Aβ and glutamate on neuronal cells, and suggested mechanisms include Aβ-induced stimulation of intracellular Ca 2þ influx, rendering the neurons vulnerable to excitotoxicity (Mattson et al., 1992) . In an AD model in rats, where bilateral hippocampal formations were sequentially treated with Aβ 1-40 and ibotenate, we previously revealed that parenchymal infusion of bFGF suppressed the progression of tissue damage in the hippocampal formation, and inhibited serious impairment to spatial learning ability (Noshita et al., 2012) . This finding indicated that bFGF was able to rescue vulnerable hippocampal neurons from toxic conditions, and restore neural function to the normal physiological state. Such beneficial functions of bFGF provide evidence for the development of medication for a number of central nervous system diseases and injuries, including AD. However, it is necessary to address the problem regarding permeability of the blood-brain barrier in the development of bFGF treatment. The present study focused on the protective activity of hippocampal neurons treated with SUN11602 (orally) under an in vivo toxic condition. In the Y-maze test, which is used to investigate short-term or spatial working memory, the injection of Aβ 1-40 followed by ibotenate into the hippocampus decreased the ratio of spontaneous alteration, an index of memory, and this decrease was inhibited by treatment with SUN11602. Importantly, SUN11602 had virtually no effect on the total number of arm entries, indicating that its effect was independent of changes in spontaneous locomotor activity. In the water maze task, used to examine learning and spatial reference memory, rats injected with Aβ 1-40 and ibotenate showed not only learning deficits in the training session (prolonged MEL), but also memory alterations (a decrease in the number of annulus crossings in a single probe trial). SUN11602 improved this learning impairment and also showed a trend to promote memory retention. This is consistent with previous findings that bFGF improves cognitive recovery in the water maze test using the same lesion model (Noshita et al., 2012) , as well as in rats following traumatic brain injury (Sun et al., 2009 ). The effect of SUN11602 was unrelated to the swimming ability of the rats, based on the absence of a difference in swimming speed between groups. 
The injection of Aβ 1-40 and ibotenate increased the number of PTBBS in rats, and SUN11602 treatment significantly attenuated their level. PTBBS have been employed as a reliable marker to demonstrate brain injury, and their numbers increase dramatically following brain lesions, reflecting the severity of gliosis in damaged brain tissue (Venneti et al., 2006) . Changes in PTBBS numbers are therefore thought to be associated with neuronal damage, which would be followed by the activation of microglia to scavenge the injured tissue (Baudry and Altar, 1991) . In this study, it was observed that the injection of Aβ 1-40 and ibotenate into rats induced an increase in the number of PTBBS, i.e. neuronal damage, and this was inhibited with SUN11602 treatment. Moreover, we found a correlation between the number of PTBBS and learning capacity (measured as escape latency during the training session) in hippocampal-lesioned rats treated with SUN11602. Collectively, it is thought that the improvement of memory and learning deficits observed in the model rats treated with SUN11602 might be, at least in part, due to protection against neuronal death.
The mechanism for the effects of SUN11602 on learning and memory deficits might also be explained by promotion of neurite outgrowth. For example, it has been reported that acute subcutaneous injection of bFGF 15 min before behavioral conditioning enhances long term memory in normal developing rats (Graham and Richardson, 2009 ). Furthermore, intracerebroventricular injection of bFGF for 2 weeks enhances production and dendritic growth of new dentate granule cells in the middle-aged hippocampus (Rai et al., 2007) . Interestingly, these findings suggest that bFGF, as well as SUN11602, might enhance learning ability in naïve rats similar to the effect observed in impaired rats, although we did not examine the effect of SUN11602 using normal rats in the present study. Another potential mechanism could be the promotion of long-term potentiation. This is because bFGF has been found to promote the generation process of longterm potentiation (Ishiyama et al., 1991) , that is considered to correlate with learning and memory ability and is impaired by the Aβ peptide (Barry et al., 2011) . It is important to note that we need to examine the mechanism of SUN11602 using the disease model in future.
In conclusion, the novel compound SUN11602 could, like bFGF, play a beneficial role in neuroprotection and neurite outgrowth in damaged hippocampal tissue. Since SUN11602 could overcome the limitations of the administration protocol for bFGF, this compound might be a promising and useful therapeutic agent for various central nervous system disorders.
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Animals
Male F344/DuCrj rats aged 10 weeks and weighing 220-250 g at the beginning of the experiments were obtained from Charles River Laboratories Japan, Inc. (Tokyo, Japan 
Preparation of primary cultures of rat neurons
Hippocampal neurons were prepared from the brains of embryonic Wistar rats (embryonic day 18 [E18]) for neurite outgrowth tests. After the brains were dissected, the hippocampi were dissociated with papain and suspended in Neurobasal medium (Invitrogen, Carlsbad, CA) containing 5% NuSerum (Japan BD, Tokyo, Japan) and 2% B27 (Invitrogen). After dissociation, hippocampal neurons were seeded on poly-D-lysine-coated 48-well plates (Falcon, Becton, Dickinson and Company, Franklin Lakes, NJ) at high density (approximately 120 cells/mm2 in 48-well plates) and cultivated in Dulbecco's modified Eagle's medium (DMEM; Gibco, Life Technologies Japan Ltd., Tokyo, Japan) supplemented with 10 mM NaHCO3, 15 mM KCl, and 1 mM sodium pyruvate. In addition, 5% (v/v) Nu-serum (Becton, Dickinson and Company) was added to the medium for hippocampal neurons. The neuronal cultures were maintained in an atmosphere of 10% CO2 at 37 1C in a humidified incubator. Four days after seeding, the proliferation of non-neuronal cells was inhibited by addition of 1 μM arabinofuranosyl cytidine (Ara-C; final concentration). The subsequent experiments were performed after 7 days. The purity of the cultures was 495% as determined by NeuN-specific immunostaining.
Quantification of neurite outgrowth
Procedures for immunocytochemistry were carried out according to accepted protocols and the manufacturer's instructions. In brief, either SUN11602 (final concentration; 0.1, 0.3, and 1 μM) or bFGF (final concentration; 1 ng/mL) was added to the culture of rat primary hippocampal neurons in poly-D-lysine-coated 48-well microplates on days 3 and 5. The neuronal culture was then fixed on day 7 with 2% paraformaldehyde and 4% sucrose in 0.1 M sodium phosphate buffer (pH 7.4) for 15 min. After treatment in 5% goat-serum blocking solution (Vector Laboratories, CA, USA) for 30 min at room temperature, neurons were incubated with primary antibodies against MAP-2 (1:5000; #ab5392, Abcam, Cambridge, UK) for 24 h at 4 1C. After several rinses, the neurons were incubated with Alexa Fluor 488 goat anti-chicken IgG as the secondary antibody (1:1000; # A11039; Life technologies, Japan Ltd., Tokyo, Japan). Quantification of neurite length and number of neurons were measured using an automated image acquisition and analysis system (IN Cell Analyzer 1000; Amersham Biosciences, Uppsala, Sweden) in the neurite assay. Immunofluorescence labeling of the MAP-2 was used to detect neurites and cell bodies of neurons.
Generation of the rat hippocampal-lesion model by sequential injections of Aβ1À 40 and ibotenate
A solution of 4 mg/mL Aβ 1-40 (Peptide Institute Inc., Japan) was prepared with saline containing 2 mM HCl and incubated for 7 days at 37 1C. The solution was distinctly turbid, and 480% of the peptide could be precipitated by centrifugation (15,000 Â g, 10 min). Ibotenic acid (Sigma-Aldrich, St. Louis, MO) was dissolved in phosphate-buffered saline (0.6 mg/mL, ibotenate solution).
A hippocampal lesion was induced as described previously (Nakamura et al., 2006) but with a slight modification. Briefly, F344 rats were anesthetized with pentobarbital sodium (50 mg/kg i.p., Nembutal s ; Dinabott, Tokyo, Japan) and placed in a stereotaxic apparatus. The skull was exposed and small holes (1 mm in diameter) were made in the parietal bone (3.0 and 4.5 mm posterior to the bregma, and one hole72.0 mm and73.5 mm lateral to the midline each, giving a total of four holes) under a surgical microscope, to avoid excessive irritation to the meninges and underlying brain. The aggregated Aβ (1 mL at 4 mg/mL) was injected bilaterally into the hippocampus using a 30-gauge needle through these holes (totaling four injection sites), according to the coordinates of the rat neuroanatomical atlas of Paxinos and Watson (1986) . A volume of 1 mL was injected at a flow rate of 0.25 mL/min for 4 min using a CMA/100 microsyringe pump. The 30-gauge needle was left in place for 2.5 min after the injection, before being withdrawn; subsequently, the surgical wound was sutured and the animals were returned to their home cages. Forty-eight hours later, ibotenate solution (0.5 mL at 0.6 mg/mL) was injected at a flow rate of 0.125 mL/min for 4 min in the same manner and using the same coordinates at which Aβ 1-40 was injected. In sham rats, an injection cannula was inserted into the above-mentioned position, without injecting the physiological saline. After surgery, the rats were kept in their home cages with free access to chow and water.
The hippocampal-lesioned model rats were evaluated using the Y-maze test (day 32), the water maze task (days 35-38), and PTBBS measurement (after completion of the water maze task).
Administration of SUN11602
SUN11602 (0.1, 1, and 10 mg/kg) was administered orally to the rat hippocampal-lesion model, once at 24 h after the Aβ 1-40 injection. In the vehicle-treated groups, saline was administered instead of SUN11602.
The Y-maze test
The Y-maze test in the hippocampal-lesioned rats was performed 32 days after the injection of Aβ 1-40 . The apparatus was manufactured from black plastic with three arms extending from a central platform at 1201. Each rat was placed at the end of one arm and allowed to move freely through the maze during a session that lasted 8 min. Arm entry was defined as all four of the animal's paws entering one arm. The sequence of arm entries was recorded visually. Alternation was defined as multiple entries into the three arms (A, B, or C) on overlapping triplet sets. The rats that were observed to have 11 arm entries or less during the test were excluded from the experiments. The percentage of spontaneous alternations was calculated as: Alternation (%) ¼[(number of alternations)/(total arm entriesÀ2)] Â 100.
The water maze task
The water maze task in the hippocampal-lesioned rats was performed according to the method of Morris (1981) . The apparatus consisted of a circular water tank with a diameter of 132 cm and a depth of 60 cm. The interior surface of the tank was covered with white tape, and the tank was filled to a depth of 45 cm with water (2472 1C) that was clouded with 0.8 kg of powdered milk. A translucent acrylic platform (10 cm diameter) was submerged 2 cm below the water surface in the center of one of the four quadrants of the maze. The tank was located in a large room with multiple external cues (including a computer, breeding cages, a calendar, and black and white graphics.). The position of the cues and the platform was constant throughout the study. The movement of the animal in the tank was monitored using a video tracking system (VIOS-88, Biomedica, Japan) and analyzed on a computer. The acquisition training study was carried out over 4 consecutive days, 35-38 days after the Aβ 1-40 injection. On the first day of acquisition, each rat was placed into the tank without an escape platform and allowed to swim for 60 s. Maze training began 3-4 h later. In each trial, the rat was put into the water at 1 of 4 starting points (north, east, south, or west) located on the edge of the tank. The starting point was changed between trials in a quasi-random manner, whereas the escape platform was fixed throughout the acquisition training. The time required to escape onto the hidden platform was recorded for each trial. If the rat found the platform, it was allowed to remain there for 10 s. If it did not find the platform within 120 s, the trial was terminated and the experimenter placed the rat onto the platform and allowed it to stay there for 10 s. The rats were trained for 4 days, with 4 trials per day, performed at 60 s intervals. A single probe trial was conducted 2 h after the final training session. For this trial, the escape platform was removed and each rat was allowed to swim for 60 s in the maze. The number of crossings of the annulus where the platform had been located was recorded.
Measurement of PTBBS
The hippocampal-lesioned rats were decapitated under ether anesthesia immediately after completion of the water maze task, and the brain was quickly excised. Peripheral-type benzodiazepine-binding sites (PTBBS) were measured as an index of gliosis and neuronal damage (Baudry and Altar, 1991) . The hippocampi were dissected out on ice and stored at À 80 1C until the assay. PTBBS were measured according to the method of Demerle-Pallardy et al. (1991) . In brief, [
3 H]-PK11195 (3163.5 GBq/mmol; NEN, Boston, MA) was used as a radiolabeled ligand for PTBBS, and the amount of this reagent that was bound to the crude hippocampus membrane was measured. The hippocampal tissue samples were homogenized in 40 volumes of homogenate buffer (50 mM Tris-HCl and 120 mM NaCl, pH 7.4). [ 3 H]-PK11195 was added to a final concentration of 2 nM and the samples were incubated at 25 1C for 60 min. The samples were then immediately filtered on a Whatman glass fiber filter (GF/B) and washed 3 times with 5 mL of ice-cold buffer. Radioactivity on the filter was measured using a liquid scintillation counter (TRI-CARB 1900CA, PACKARD), and the amount of ligand bound to cell membranes was calculated by subtracting the nonspecific binding in the presence of PK11195 (1 mM) from the total binding. Furthermore, the protein content of the tissue sample was determined using the method of Smith et al.
